Phase II Trial Evaluating Axitinib (AG-013736) In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2016
At a glance
- Drugs Axitinib (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 26 Jul 2016 Status changed from active, no longer recruiting to completed.
- 08 Mar 2016 Planned End Date changed from 1 Jan 2016 to 1 Jun 2016, according to ClinicalTrials.gov record.